MARCKS and inflammatory breast carcinoma: We focused on MARCKS protein expression for several reasons: i) strong differential mRNA expression between IBC and non-IBC clinical samples in the largest transcriptomics study reported to date and stratified upon molecular subtypes [7]; ii) proven role of MARCKS in cancer progression including metastatic process and therapeutic resistance; iii) ongoing development of MARCKS inhibitors; iv) commercial availability of a corresponding monoclonal antibody performing sufficiently well in IHC on paraffin-embedded tissues as previously reported [18, 21].